Millions of People Are Quitting Ozempic Once They Hit Their Goal Weight — New Research Shows That Could Raise Heart Attack and Stroke Risk by 22%
A pharmacist's guide to a major new WashU Medicine study showing how quickly the cardiovascular protection from GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound can disappear after stopping — and what "metabolic whiplash" means for the roughly one in eight American adults currently using these medications.
Most of the conversation around GLP-1 drugs — Ozempic, Wegovy, Mounjaro, Zepbound — has focused on what happens while you're taking them: the appetite suppression, the weight loss, the well-documented side effects. Almost none of it has focused on what happens after you stop, even though stopping is exactly what roughly half of all users end up doing, often within months, usually because of cost, side effects, or simply reaching a goal weight.
A major new study published in BMJ Medicine, led by researchers at Washington University in St. Louis, has now put hard numbers behind that overlooked question, and the answer is sobering: the cardiovascular protection these drugs provide can begin eroding within as little as six months of stopping, and after two years off treatment, patients face up to a 22% higher risk of heart attack, stroke, and death compared to those who stayed on the medication. This guide breaks down exactly what the study found, why the researchers describe this as "metabolic whiplash," what it means for the roughly one in eight American adults currently using these drugs, and what questions are worth asking before you consider stopping.
The research, led by senior author Dr. Ziyad Al-Aly, a clinical epidemiologist at WashU Medicine and chief of the Research and Development Service at the VA Saint Louis Health Care System, followed more than 333,000 U.S. veterans with type 2 diabetes over approximately three years. Researchers compared 132,551 participants prescribed GLP-1 medications against 201,136 participants prescribed sulfonylureas (an older class of diabetes medication, including drugs like glipizide, glimepiride, and glyburide), tracking participants' health status every six months and recording major adverse cardiovascular events — heart attack, stroke, and death.
Dr. Al-Aly explained the motivation behind the research plainly: after noticing that roughly half of GLP-1 users stop taking the medication relatively soon after starting, his team wanted to understand not just what happens to weight after people stop, which prior research had already examined, but specifically what happens to cardiovascular health.
| Pattern Observed | Cardiovascular Risk Change |
|---|---|
| Continuous GLP-1 use for 3 years | 18% reduction in major cardiovascular events compared with sulfonylurea users |
| Discontinued after 2.5 years, no restart | 15% reduction in risk (benefit already declining compared to continuous use) |
| Discontinued after 2 years, no restart | 7% reduction in risk |
| Discontinued at 18 months or less | No statistically significant risk reduction remaining |
| Interrupted for 6 months, then resumed | 4-8% increase in risk compared with continuous, uninterrupted use |
| Off treatment for 1 year (no restart) | 14% higher risk of major cardiovascular events |
| Off treatment for 2 years (no restart) | Up to 22% higher risk of heart attack, stroke, and death |
The pattern that emerges from these numbers is strikingly consistent: the longer someone stayed on the medication, the more cardiovascular protection they accumulated — but that protection wasn't stored up or permanent. The longer someone went without treatment after stopping, the more that protection eroded, in a clear, graded, dose-and-duration-dependent relationship in both directions.
Understanding why this finding matters so much requires understanding just how common discontinuation actually is. This isn't a fringe pattern affecting a small minority of users — it's closer to the norm.
| Reason for Stopping | What the Broader Data Shows |
|---|---|
| Cost | Frequently cited as the single most common reason patients discontinue treatment, particularly once insurance coverage changes or out-of-pocket costs become unsustainable |
| Side effects | GI side effects and other tolerability issues lead a meaningful share of users to stop, especially in the first several months |
| Reaching a goal weight | Some patients and even some prescribers view GLP-1 treatment as a temporary intervention to reach a target, rather than the long-term, ongoing therapy the underlying condition may actually require |
| Supply and access disruptions | Periods of medication shortage or insurance formulary changes have caused unintentional treatment gaps for some patients |
A separate study of more than 157,000 first-time semaglutide users in Denmark found that 49% discontinued the drug within 12 months, and about a quarter of those who stopped ended up restarting within three months — a pattern of stopping and starting that, based on this new research, may itself carry meaningful cardiovascular consequences beyond a single clean discontinuation.
Dr. Al-Aly used a specific and memorable phrase to describe what appears to be happening physiologically: "metabolic whiplash." Understanding what's actually reversing helps explain why the cardiovascular risk climbs back so quickly.
Beyond weight loss itself, GLP-1 drugs are known to reduce cholesterol, blood pressure, chronic inflammation, and insulin resistance — each an independent contributor to cardiovascular risk in its own right. According to Dr. Al-Aly, "when people stop, these start going in the wrong direction," meaning the multiple risk factors these drugs simultaneously improve don't simply plateau after discontinuation — they actively reverse, in some cases relatively quickly.
The study also examined what happens to cardiovascular risk in people who stopped and later resumed treatment, and the findings suggest restarting helps, but doesn't fully undo the damage from the gap.
Participants who experienced an interruption in treatment before resuming saw an average 12% reduction in cardiovascular risk, compared to the 18% reduction seen in those who used the medication continuously for three years without interruption. Dr. Al-Aly summarized this pattern directly: "Restarting the medication helped restore some protection, but only partially, showing that discontinuation leaves a lasting scar."
To understand why stopping has such a measurable effect, it helps to understand what these drugs are believed to be doing for cardiovascular health beyond weight loss alone.
Beyond their well-known effects on appetite and blood sugar, GLP-1 receptor agonists appear to reduce the underlying inflammatory processes that drive heart attacks, strokes, and heart failure over time — a mechanism distinct from, and likely additive to, their effects on weight, blood pressure, and cholesterol. This is part of why these drugs have increasingly been studied and, in some cases, specifically approved for cardiovascular risk reduction, not just diabetes and weight management.
As with any single study, it's worth being precise about what this research does and doesn't establish.
This new cardiovascular finding doesn't stand alone — it fits into a broader, increasingly well-documented pattern of what happens when GLP-1 treatment stops.
| Consequence of Stopping | Supporting Evidence |
|---|---|
| Substantial weight regain | A separate review synthesizing evidence from more than 289,000 patients found that 60-90% of lost weight may return within a year of stopping |
| Reversal of blood sugar, blood pressure, and cholesterol improvements | The same review found these metabolic improvements can reverse once treatment stops |
| Increased coronary artery disease and heart failure risk within the first year of stopping | A March 2026 review in Diabetes, Obesity and Metabolism found elevated risk specifically in the first year after discontinuation |
| Loss of cardiovascular risk factor improvements more broadly | A May 2026 review in Nature Reviews Endocrinology similarly found that stopping commonly leads to rising blood sugar and loss of cardiovascular risk factor improvements |
Taken together, this body of research increasingly points in one consistent direction: for many patients, GLP-1 drugs function less like a course of treatment with a defined endpoint and more like an ongoing therapy whose benefits — metabolic, cardiovascular, and otherwise — are closely tied to continued use.
| Group | Why This Finding Is Especially Relevant |
|---|---|
| Anyone considering stopping after reaching a weight-loss goal | The framing of GLP-1 treatment as a temporary fix to reach a target, rather than an ongoing therapy, appears to directly conflict with what this research shows about sustained benefit |
| Anyone at risk of stopping due to cost or insurance changes | An involuntary treatment gap carries the same measured risk increase as a voluntary one, making cost-related access barriers a cardiovascular concern, not just a financial and weight-management one |
| People with type 2 diabetes and existing cardiovascular risk factors | This is the specific population studied, and the population for whom the cardiovascular stakes of discontinuation are most directly established by this research |
| People who have already experienced a treatment gap and resumed | Understanding that restarting only partially restores lost protection is directly relevant to anyone in this situation |
If you're currently taking a GLP-1 medication for either diabetes or weight management, this research supports thinking about it similarly to how you'd think about a blood pressure or cholesterol medication — a therapy whose benefits are tied to continued use, rather than a short course meant to be discontinued once a target is reached.
Because cost is such a common reason for discontinuation, and because this research suggests real cardiovascular stakes to stopping, it's worth proactively discussing cost concerns with your prescriber before a gap happens, rather than after — they may be aware of patient assistance programs, alternative formulations, or other options.
If you're considering pausing treatment for any reason, understand from this research that even a temporary gap appears to carry a measurable, and only partially reversible, cardiovascular cost — this is worth weighing explicitly rather than assuming a pause is simply neutral.
If you've already gone through a stop-and-restart cycle, this research suggests some of that cardiovascular benefit may not be fully recoverable — worth discussing with your doctor as part of your broader cardiovascular risk picture going forward, rather than assuming you're back to your prior risk level.
Given what's now understood about both weight regain and cardiovascular risk after stopping, any decision to discontinue is worth a specific, deliberate conversation with your prescriber about timing, alternatives, and monitoring — rather than simply not refilling a prescription.
Not necessarily — there are legitimate medical reasons someone might need to stop, including side effects, other health changes, or a clinical decision made with their doctor. What this research suggests is that stopping isn't a cost-free decision from a cardiovascular standpoint, and it should be made deliberately and in conversation with your prescriber, rather than treated as a default once a weight goal is reached or as an unavoidable consequence of a temporary supply or cost issue without further discussion.
This specific study focused on people with type 2 diabetes, so it doesn't directly measure outcomes in people using these drugs solely for weight management without diabetes. However, the broader body of research on weight regain and reversal of cardiovascular risk factors after stopping — blood pressure, cholesterol, inflammation — is relevant to a wider population, and the underlying mechanism (metabolic benefits reversing after discontinuation) isn't inherently specific to a diabetes diagnosis. This is worth discussing with your own prescriber given your specific situation.
Possibly — manufacturers have been working to expand access and affordability, and your prescriber may be aware of patient assistance programs, alternative formulations, or other resources specific to your insurance situation. Given what this research shows about the cardiovascular stakes of an involuntary gap, it's worth raising cost concerns proactively rather than simply stopping without exploring these options first.
Based on this study, not fully. Participants who resumed treatment after an interruption saw an average 12% cardiovascular risk reduction, compared to 18% in those who used the medication continuously without interruption — suggesting the gap leaves some lasting impact even after treatment resumes.
According to this study, an interruption of as little as six months before resuming was associated with a measurable 4-8% increase in risk compared to continuous use, with the risk climbing further the longer the gap continued — reaching up to 22% higher risk after a full two years off treatment without restarting.
This was a large, carefully designed observational study, not a randomized controlled trial, so it cannot definitively prove causation the way a randomized trial would. However, the researchers used target trial emulation methodology specifically to approximate that level of rigor, and the consistent, graded, dose-and-duration-dependent pattern of the findings, along with alignment with other independent research on weight regain and cardiovascular risk factor reversal, makes a causal relationship a reasonable and well-supported interpretation.
This phrase describes the pattern the researchers observed in which the multiple metabolic improvements GLP-1 drugs provide — weight loss, lower cholesterol, lower blood pressure, reduced inflammation, improved insulin resistance — don't simply plateau after stopping, but appear to actively reverse, contributing to the relatively rapid rise in cardiovascular risk documented in the study.
This is an individualized clinical decision that depends on your specific health situation, other risk factors, and goals, and should be made in conversation with your doctor rather than based on a general rule. What this research does support is treating any decision to stop as a deliberate one with real cardiovascular considerations, rather than an incidental or default outcome of reaching a weight goal or facing a temporary access barrier.
This article is for educational purposes only and does not constitute medical advice. It summarizes findings from an observational study published in BMJ Medicine (2026) and related research, and does not diagnose or rule out any individual's condition or personal cardiovascular risk. Do not start, stop, or change any GLP-1 medication or other prescription based on this article alone. If you are considering stopping a GLP-1 medication, for any reason, discuss the decision, timing, and any appropriate monitoring with your prescriber first. This content reflects research findings current as of September 2026, and further studies may refine or expand on what's described here.
Millions of People Are Quitting Ozempic Once They Hit Their Goal Weight — New Research Shows the Risk
Millions of People Take Calcium and Vitamin D Every Day for Bone Health, A Massive New Review Just Found It Barely Works (2026)
The "Menopause Cocktail" Taking Over TikTok — Why Millions of Women Are Mixing Allegra and Pepcid Daily, and What Doctors Want You to Know First (2026)
Why the Same Medicine Will Work Differently on You in 2027 (Personalized Medicine Is Coming — Here's What Patients Need to Know)